We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Evaluation of factors affecting epidermal growth factor receptor tyrosine kinase inhibitor-induced hepatotoxicity in Japanese patients with non-small cell lung cancer: a two-center retrospective study.
- Authors
Nagai, Hirofumi; Shimada, Tsutomu; Takahashi, Yoshimitsu; Nishikawa, Mikako; Tozuka, Hiroyuki; Yamamoto, Yasuto; Niwa, Osamu; Takahara, Yutaka; Fujita, Arimi; Nagase, Katsuhiko; Kasahara, Kazuo; Yano, Seiji; Sai, Yoshimichi
- Abstract
Background: Gefitinib and erlotinib, are epidermal growth factor receptor tyrosine kinase inhibitors, and are currently recommended for non-small cell lung cancer stage IV in the elderly and in patients with decreased performance status in the Japanese Lung Cancer Society Guideline, but they occasionally caused severe hepatotoxicity requiring postponement or modification of treatment. However, little is known about the risk factors for hepatotoxicity in patients receiving gefitinib and erlotinib. In this study, we investigated the factors influencing hepatotoxicity in Japanese non-small cell lung cancer (NSCLC) patients treated with gefitinib or erlotinib monotherapy. Methods: Japanese patients with NSCLC who started gefitinib or erlotinib monotherapy from January 2005 to December 2017 at Kanazawa University Hospital or Kanazawa Medical University Hospital were included in this study. Factors affecting hepatotoxicity were retrospectively investigated by multiple logistic regression analysis. Results: A total of 102 patients who received gefitinib and 95 patients who received erlotinib were included in the analysis. In the gefitinib group, a body mass index (BMI) ≥ 25 was associated with an increased risk of hepatotoxicity (OR = 4.571, 95% CI = 1.486–14.056, P = 0.008). In the erlotinib group, concomitant use of acid-suppressing medications (AS), namely proton pump inhibitors or histamine-2 receptor antagonists, was associated with a reduced risk of hepatotoxicity (OR = 0.341, 95% CI = 0.129–0.900, P = 0.030). Conclusions: BMI ≥ 25 in patients treated with gefitinib increased the risk of hepatotoxicity. In contrast, AS combination with erlotinib reduced the risk of hepatotoxicity. Thus, because different factors influence the risk of hepatotoxicity, monitoring for adverse events should take into account patient background factors and concomitant medications.
- Subjects
EPIDERMAL growth factor receptors; NON-small-cell lung carcinoma; EPIDERMAL growth factor; PROTEIN-tyrosine kinases; JAPANESE people; HEPATOTOXICOLOGY
- Publication
Journal of Pharmaceutical Health Care & Sciences, 2022, Vol 8, Issue 1, p1
- ISSN
2055-0294
- Publication type
Article
- DOI
10.1186/s40780-022-00258-7